摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 6-isocyano-1H-indazole-1-carboxylate | 1430115-41-5

中文名称
——
中文别名
——
英文名称
tert-butyl 6-isocyano-1H-indazole-1-carboxylate
英文别名
tert-butyl 6-isocyanoindazole-1-carboxylate
tert-butyl 6-isocyano-1H-indazole-1-carboxylate化学式
CAS
1430115-41-5
化学式
C13H13N3O2
mdl
——
分子量
243.265
InChiKey
HEXQWFSPOQZVTO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    48.5
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    tert-butyl 6-isocyano-1H-indazole-1-carboxylate三氟乙酸 作用下, 以 甲醇二氯甲烷 为溶剂, 反应 2.0h, 生成 2-[3-chloro-4-(cyclopropylmethoxy)-N-prop-2-ynoylanilino]-N-(1H-indazol-6-yl)-3,3-dimethylbutanamide
    参考文献:
    名称:
    [EN] GPX4 INHIBITORS AND USE THEREOF
    [FR] INHIBITEURS DE GPX4 ET LEUR UTILISATION
    摘要:
    The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, specifically in treating cancer or autoimmune diseases. This disclosure also features a composition containing the same as well as methods of using and making the same.
    公开号:
    WO2024030651A1
  • 作为产物:
    描述:
    二碳酸二叔丁酯 在 palladium 10% on activated carbon 、 氢气三乙胺N,N'-二环己基碳二亚胺三氯氧磷 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 tert-butyl 6-isocyano-1H-indazole-1-carboxylate
    参考文献:
    名称:
    [EN] GPX4 INHIBITORS AND USE THEREOF
    [FR] INHIBITEURS DE GPX4 ET LEUR UTILISATION
    摘要:
    The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, specifically in treating cancer or autoimmune diseases. This disclosure also features a composition containing the same as well as methods of using and making the same.
    公开号:
    WO2024030651A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS<br/>[FR] COMPOSÉS TÉTRAHYDROISOQUINOLINES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013055984A1
    公开(公告)日:2013-04-18
    The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    本发明提供了化合物的公式(I):或其立体异构体,以及其药学上可接受的盐,其中所有变量如本文所定义。这些化合物是XIa因子和/或血浆激肽酶的抑制剂,可用作药物。
  • [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013056034A1
    公开(公告)日:2013-04-18
    The present invention provides compounds of Formula (I) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    本发明提供了式(I)的化合物或立体异构体,以及其药学上可接受的盐,其中所有变量均如本文所定义。这些化合物是因子XIa和/或血浆激肽原抑制剂,可用作药物。
  • Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    申请人:Bristol-Myers Squibb Company
    公开号:US09000172B2
    公开(公告)日:2015-04-07
    The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    本发明提供了式(I)的化合物:或其立体异构体,其药学上可接受的盐,其中所有变量如本文所定义。这些化合物是XIa因子和/或血浆卡利肌酶的抑制剂,可用作药物。
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160075715A1
    公开(公告)日:2016-03-17
    The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    本发明提供了式(I)的化合物或其立体异构体,以及其药学上可接受的盐,其中所有变量均如本文所定义。这些化合物是XIa因子和/或血浆卡利肌酶的抑制剂,可以用作药物。
查看更多